Coherus Oncology, Inc. (FRA:8C5)
Germany · Delayed Price · Currency is EUR | Market Cap | 181.38M +48.8% |
| Revenue (ttm) | 44.58M +61.0% |
| Net Income | -115.66M |
| EPS | -0.88 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.155 |
| Previous Close | 1.152 |
| Day's Range | 1.155 - 1.155 |
| 52-Week Range | 0.943 - 2.188 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Coherus Oncology
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo... [Read more]
Financial Performance
In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.
Financial numbers in USD Financial StatementsNews
Coherus Oncology issuing special dividend of biosimilar contingent value rights
Coherus Oncology (CHRS) announced a special dividend of contingent value rights which will be distributed on a pro rata basis to stockholders of record as of September 30. The distribution…
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company ...
Coherus Oncology price target lowered to $10 from $12 at Guggenheim
Guggenheim lowered the firm’s price target on Coherus Oncology (CHRS) to $10 from $12 and keeps a Buy rating on the shares.
Coherus Oncology reports Q2 EPS (19c), consensus (12c)
Reports Q2 revenue $14.31M, consensus $20.44M. “During the second quarter we continued to pursue our science-driven clinical development strategy, creating multiple avenues for long-term value creatio...
Coherus Oncology Earnings Call Transcript: Q2 2026
Q2 2026 saw strong LOQTORZI sales growth, reduced operating expenses, and significant progress in clinical programs, with key data readouts expected later in the year. The company remains financially stable post-divestiture and anticipates continued commercial and pipeline momentum.
Coherus Oncology Earnings release: Q2 2026
Coherus Oncology released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Coherus Oncology Quarterly report: Q2 2026
Coherus Oncology has published its Q2 2026 quarterly earnings report on August 5, 2026.
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – ...
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2...
Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study
Coherus Oncology (CHRS) and Zumutor Biologics announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a NK checkpoint anti-LLT1 monoclonal antibody in combination ...
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008,...
Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust immuno-oncology pipeline, with LOQTORZI driving commercial growth and serving as a backbone for novel combinations. Tagmokitug and casdozokitug are advancing in multiple indications, with key data and global deals expected over the next 6–18 months.
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Transcript: AGM 2026
The meeting approved director elections, auditor ratification, executive compensation, and an increase in equity plan shares. The proposal to reduce stock option exercise prices was adjourned for further voting, with the Q&A session postponed until all business is concluded.
Coherus Oncology reports Q1 EPS (28c), consensus (26c)
Reports Q1 revenue $12.31M, consensus $14.34M. “We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination wit...
Coherus Oncology Earnings Call Transcript: Q1 2026
Q1 2026 saw 61% year-over-year LOQTORZI sales growth, robust new patient starts, and strong pipeline progress despite seasonal headwinds. The company raised $54 million, maintains $167 million in cash, and expects continued double-digit quarterly demand growth for LOQTORZI.
Coherus Oncology Earnings release: Q1 2026
Coherus Oncology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Coherus Oncology Quarterly report: Q1 2026
Coherus Oncology has published its Q1 2026 quarterly earnings report on May 11, 2026.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projectio...
Guggenheim starts Coherus with Buy on anti-tumor potential
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target Coherus recently completed a transformation from a biosimilars platform to a pure-play immuno-oncology c...
Coherus Oncology initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Coherus Oncology (CHRS) with a Buy rating and $12 price target
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monda...
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Coherus Oncology Proxy statement: Proxy filing
Coherus Oncology filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.